Publications by authors named "P Isomaki"
Objectives: To elucidate the risk and temporal relationship of cardiovascular (CV) comorbidities in rheumatic diseases.
Methods: Patients in the FinnGen study diagnosed between 2000 and 2014 with seropositive (n = 2368) or seronegative (n = 916) rheumatoid arthritis (RA), ankylosing spondylitis (AS, n = 715), psoriatic arthritis (PsA, n = 923), systemic lupus erythematosus (SLE, n = 190), primary Sjogren's syndrome (pSS, n = 412) or gout (n = 2034) were identified from healthcare registries. Each patient was matched based on age, sex, and birth region with twenty controls without any rheumatic conditions.
Article Synopsis
- The study aimed to evaluate the selectivity of various JAK inhibitors (Jakinibs) for JAK and cytokine activity, particularly in the context of rheumatic diseases, despite a lack of comprehensive direct comparisons.
- The researchers tested 10 different Jakinibs using blood samples from healthy volunteers and rheumatoid arthritis patients, finding that pan-Jakinibs suppressed multiple JAK family members while isoform-targeted Jakinibs showed selectivity for one or two members.
- Results indicated that all Jakinibs predominantly inhibited JAK1-dependent cytokines, with some novel inhibitors showing exceptionally high selectivity, but overall, the patterns of cytokine inhibition among currently approved Jakinibs were quite similar.
Article Synopsis
- The study aimed to assess the risk of blood cancers in patients with psoriatic arthritis (PsA) and specifically examine any potential risks associated with treatment using tumor necrosis factor inhibitors (TNFi).
- Researchers analyzed data from clinical rheumatology registers in five Nordic countries, focusing on patients who started TNFi treatment compared to those who had never received biologic treatment.
- Results showed that TNFi treatment did not correlate with a higher incidence of blood cancers; however, patients with PsA overall did have a slightly elevated risk compared to the general population.
The data on the effects of tofacitinib on soluble proteins in patients with rheumatoid arthritis (RA) is currently very limited. We analyzed how tofacitinib treatment and thus inhibition of the Janus kinase-signal transducer and activation of transcription pathway affects the in vivo levels of inflammation-related plasma proteins in RA patients. In this study, 16 patients with active RA [28-joint disease activity score (DAS28) >3.
View Article and Find Full Text PDFGorham-Stout disease with life-threatening pleural effusion treated with a pleuro-peritoneal shunt: a case report.
Endocrinol Diabetes Metab Case Rep
June 2022
Summary: Gorham-Stout disease (GSD) is a rare bone disease characterized by massive osteolysis and lymphatic proliferation. The origin of the condition is unknown, and no established treatment protocol exists. Massive pleural effusion is a frequent complication of GSD in the thoracic region.
View Article and Find Full Text PDF